Alexander Eser

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Vaccination of immunocompromised individuals: Expert opinion - update 2026

Vaccination of immunocompromised individuals: Expert opinion - update 2026

Journal: Wiener klinische Wochenschrift

Published: April 14, 2026

Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases.

Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases.

Journal: Journal of clinical medicine

Published: May 02, 2022

Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management.

Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management.

Journal: British journal of clinical pharmacology

Published: June 06, 2020

Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection.

Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection.

Journal: Journal of clinical pharmacology

Published: April 30, 2020

Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System.

Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System.

Journal: Journal of clinical pharmacology

Published: September 14, 2017

Guidelines for vaccination of immunocompromised individuals

Guidelines for vaccination of immunocompromised individuals

Journal: Wiener klinische Wochenschrift

Published: May 25, 2016

Platelets Toll-like receptor-4 in Crohns disease.

Platelets Toll-like receptor-4 in Crohns disease.

Journal: European journal of clinical investigation

Published: April 10, 2016

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.

Journal: Alimentary pharmacology & therapeutics

Published: October 28, 2015

Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.

Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.

Journal: Inflammatory bowel diseases

Published: July 22, 2015

Early recognition of possible pitfalls in histological diagnosis of celiac disease.

Early recognition of possible pitfalls in histological diagnosis of celiac disease.

Journal: Scandinavian journal of gastroenterology

Published: February 21, 2015

Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease.

Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease.

Journal: Journal of Crohn's & colitis

Published: August 10, 2013

Drug monitoring of biologics in inflammatory bowel disease.

Drug monitoring of biologics in inflammatory bowel disease.

Journal: Current opinion in gastroenterology

Published: May 25, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026